echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Brief introduction of drugs accepted by CDE in March 2014

    Brief introduction of drugs accepted by CDE in March 2014

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In March 2014, the CDE received 745 drug applications, an increase of nearly 40% over February

    Among them, 212 new drug applications, 193 copy applications and 68 import applications all increased to varying degrees compared with February

    Figure distribution of drug application types accepted by CDE in March 2014 All the new drug applications registered as category 1 are clinical applications for new drugs, with 16 applications involving 7 varieties, all of which are chemicals, including 6 varieties of 1.1 and 1 variety of 1.6

    In addition to the treatment category of shr4640 APIs and preparations declared by Hengrui pharmaceutical, 5 of the other 6 varieties are anti-tumor drugs, and 1 variety is mental disorder drugs

    Shenyang Pharmaceutical University applied Mitoxantrone Hydrochloride Injection for lymph tracing

    The tracer is usually used to clean the peripheral lymph nodes, especially after tumor resection

    Mitoxantrone is commonly used in malignant lymphoma, breast cancer and all kinds of acute leukemia

    There should be micro innovation in the structure of mitoxantrone for tracing, so it should be applied as a new drug of 1.1

    Peg-sn38 is a camptothecin derivative, and Haizheng pharmaceutical is licensed from enzonpharmaceuticals

    Peg-sn38 is a polyethylene glycol modifier of sn38 (3-ethyl-10-hydroxy-camptothecin, the active metabolite of irinotecan)

    Enzonpharmaceuticals has published the phase I clinical trial results of peg-sn38 in the treatment of recurrent / refractory neuroblastoma and other solid tumors in children

    Sklb1028 is a multi-target tyrosine kinase inhibitor obtained by Shiyao group from Sichuan University, which can act on EGFR, FLT3 and ABL

    The transfer price of sklb1028 is 20 million yuan

    Another tyrosine kinase inhibitor, mehuatinib, has been declared by Huadong pharmaceutical

    So far, CDE has accepted more than 20 varieties of tinib class 1 new drugs

    The irinotecan hydrochloride liposome injection declared by orsacom is of class 1.6

    At the same time, orsacom has also submitted an application for the registration of the variety as class 5

    Prior to this, Hengrui pharmaceutical and Qilu pharmaceutical respectively submitted clinical applications for this variety in 2011 and 2013, with registration classification of 5 categories

    As HT receptor agonist / 5-HT reuptake inhibitor, mepyridone is used to treat depression

    It is a project jointly developed by Huahai pharmaceutical and Academy of Military Medical Sciences

    It is also the first class 1 new drug declared by Huahai pharmaceutical, reflecting the improvement of Huahai pharmaceutical's R & D line positioning

    Table 1 clinical application of new drugs of category 1 accepted by CDE in March 2014
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.